[CAS NO. 357-70-0] Galanthamine

Name: Galanthamine
Brand: Arctom Scientific
SKU: HY-76299

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [357-70-0]

Distributor

Catalog

HY-76299

Brand

MCE

CAS

357-70-0

DESCRIPTION [357-70-0]

Overview

MDL	MFCD00867189
Molecular Weight	287.35
Molecular Formula	C17H21NO3
SMILES	O[C@@H]1C[C@@H]2OC3=C4C(CN(C)CC[C@]42C=C1)=CC=C3OC

For research use only. We do not sell to patients.

8 Publications Citing Use of MCE

Summary

Galanthamine is a potent acetylcholinesterase ( AChE ) inhibitor with an IC ₅₀ of 500 nM.

IC50 & Target

AChE

In Vitro

Galanthamine inhibits AChE and BChE with IC ₅₀ of 0.5 and 8.5 μM ^[1] . Galanthamine acts as a positive allosteric modulator (PAM) of human α4β2 AChRs expressed in permanently transfected HEK 293 cells. Galanthamine increases the response of (α4β2) ₂ α5 AChRs to 1 μM ACh by up to 220% with very low concerntration(EC ₅₀ =0.25 nM). Only small potentiation (20%) of either α4β2 or (α4β2) ₂ β3 AChRs is detected using FLEXstation assays. Galanthamine at concentrations of 1 μM and above inhibits all three AChR subtypes ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Acute administration of Galantamine (0.3-3 mg/kg, i.p.) increases IGF2 mRNA levels in the hippocampus, but not in the prefrontal cortex, in time- and dose-dependent manner. Galantamine (3 mg/kg, i.p.) causes a transient increase in fibroblast growth factor 2 mRNA levels and a decrease in brain-derived neurotrophic factor mRNA levels in the hippocampus, while it does not affect the mRNA levels of other neurotrophic/growth factors. The Galantamine-induced increase in the hippocampal IGF2 mRNA levels is blocked by Mecamylamine, a nonselective nicotinic acetylcholine (ACh) receptor (nAChR) antagonist, and Methyllycaconitine, a selective α7 nAChR antagonist, but not by Telenzepine, a preferential M1muscarinic ACh receptor antagonist. Moreover, the selective α7 nAChR agonist PHA-543613 increasea the IGF2 mRNA levels, while Donepezil, an acetylcholinesterase inhibitor, does not. Galantamine also increases hippocampal IGF2 protein, which is blocked by Methyllycaconitine ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00164242	Caroff, Stanley N., M.D.\|Ortho-McNeil Neurologics, Inc.	Tardive Dyskinesia	January 2002	Phase 4
NCT01478633	Janssen Pharmaceutical K.K.	Alzheimer´s Disease	September 2011	Phase 4
NCT00181675	Massachusetts General Hospital	ADHD	December 2002	Phase 4
NCT02365285	Vanderbilt University Medical Center\|Doris Duke Charitable Foundation	Obesity	March 2015	Phase 1\|Phase 2
NCT02098824	Amsterdam UMC, location VUmc	Mild Cognitive Impairment (Vascular)\|Mild Cognitive Disorder (Vascular)\|Vascular Dementia	February 2014	Phase 2\|Phase 3
NCT01009476	Janssen-Cilag G.m.b.H	Dementia\|Alzheimer Disease\|Dementia, Vascular	March 2006
NCT00176423	University of Maryland, Baltimore\|Stanley Medical Research Institute\|Ortho-McNeil Neurologics, Inc.	Schizophrenia\|Schizoaffective Disorder	May 2002	Phase 4
NCT00253214	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Alzheimer Disease\|Dementia	March 2001	Phase 3
NCT00814801	Janssen Pharmaceutical K.K.	Alzheimer´s Disease	February 2007	Phase 3
NCT00227994	University of Pittsburgh\|National Institute of Mental Health (NIMH)	Cerebrovascular Accident	April 2003	Phase 4
NCT04769206	Vanderbilt University Medical Center	Endothelial Dysfunction	December 20, 2021	Phase 1\|Phase 2
NCT00240695	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Cognition Disorder\|Nervous System Diseases\|Mental Disorders\|Brain Diseases	May 2003	Phase 3
NCT00741598	Icahn School of Medicine at Mount Sinai\|National Institute of Mental Health (NIMH)\|Massachusetts General Hospital	Bipolar Disorder	September 2008	Phase 4
NCT01190761	Actavis Inc.	Healthy	December 2004	Phase 1
NCT02374567	Hannover Medical School	Dementia\|Depression\|Schizophrenia\|Psychosomatic Disorders\|Anxiety Disorders	January 2015	Phase 3
NCT00253227	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Alzheimer Disease\|Dementia	July 1997	Phase 3
NCT00523666	Ludwig-Maximilians - University of Munich	Alzheimer´s Disease	September 2006	Phase 4
NCT00301574	Janssen Pharmaceutical K.K.	Alzheimer Disease	April 2001	Phase 3
NCT00232349	Seattle Institute for Biomedical and Clinical Research	Schizophrenia\|Psychotic Disorder	February 2005	Phase 4
NCT00423969	Indiana University School of Medicine\|Indiana University	Depression	November 2003	Phase 4
NCT01362686	Indiana University\|Agency for Healthcare Research and Quality (AHRQ)	Dementia\|Alzheimer´s Disease	April 2011	Not Applicable
NCT01508494	Institut National de la Santé Et de la Recherche Médicale, France	Stroke\|Cognitive Impairment	June 29, 2011	Phase 2
NCT00035191	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Dementia, Vascular	October 2001	Phase 3
NCT00304629	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Alzheimer Disease	March 2000	Phase 3
NCT00297362	Janssen Cilag Pharmaceutica S.A.C.I., Greece	Alzheimer Disease	June 2004
NCT00679627	Janssen Research & Development, LLC	Alzheimer´s Disease	June 2008	Phase 3
NCT01190748	Actavis Inc.	Healthy	November 2004	Phase 1
NCT00299676	Janssen-Cilag Pty Ltd	Alzheimer Disease\|Dementia\|Galantamine	May 2005
NCT01194336	U.S. Army Medical Research and Development Command\|Walter Reed Army Institute of Research (WRAIR)	Biomarkers, Pharmacological	February 2012
NCT00082602	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.\|Ortho-McNeil Neurologics, Inc.	Alzheimer´s Disease	May 2004	Phase 3
NCT00236574	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Dementia\|Alzheimer Disease	May 2001	Phase 3
NCT00216515	Janssen Korea, Ltd., Korea	Alzheimer Disease	March 2004	Phase 4
NCT03547622	Yale University\|National Institute on Drug Abuse (NIDA)	Methadone or Buprenorphine Detoxoxification	May 1, 2018	Early Phase 1
NCT01039194	Bristol-Myers Squibb	Alzheimer Disease	January 2010	Phase 1
NCT00252603	University of Medicine and Dentistry of New Jersey\|National Alliance for Autism Research\|Rutgers, The State University of New Jersey	Autism\|Childhood Autism	April 2004	Phase 3
NCT00261573	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Alzheimer Disease\|Vascular Dementia	December 1998	Phase 3
NCT01921972	Charite University, Berlin, Germany\|German Federal Ministry of Education and Research	Alzheimer´s Disease	November 2004	Phase 4
NCT02283242	University of Sao Paulo\|University of Nove de Julho\|Feinstein Institute for Medical Research	Abdominal Obesity Metabolic Syndrome	March 2014	Phase 4
NCT01669538	University of Pennsylvania\|National Institutes of Health (NIH)\|National Cancer Institute (NCI)\|National Center for Research Resources (NCRR)\|National Institute on Drug Abuse (NIDA)	Tobacco Use Disorder	August 2012	Phase 2
NCT00606801	Yale University\|National Institute on Drug Abuse (NIDA)	Cocaine Abuse	June 2007	Not Applicable
NCT01677754	Hoffmann-La Roche	Alzheimer´s Disease	October 24, 2012	Phase 2
NCT00219869	Rapoport, Alan, M.D.\|Ortho-McNeil Neurologics, Inc.	Post-Traumatic Headache\|Head Trauma,Closed\|Retention Disorders,Cognitive	July 2005	Phase 4
NCT00253201	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Alzheimer Disease\|Dementia		Phase 3
NCT00645554	Xian-Janssen Pharmaceutical Ltd.	Pharmacokinetics		Phase 1
NCT00253188	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Alzheimer Disease\|Dementia	February 1997	Phase 3
NCT00216502	Janssen-Cilag S.p.A.	Alzheimer Disease\|Dementia\|Mental Disorders\|Brain Diseases	August 2001	Phase 3
NCT01181921	Janssen-Cilag, S.A.	Alzheimer Disease	May 2011	Phase 4
NCT00211588	Memorial Hospital of Rhode Island\|Ortho-McNeil Neurologics, Inc.	Parkinson´s Disease	June 2004	Not Applicable
NCT00035204	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.\|Ortho-McNeil Neurologics, Inc.	Alzheimer Disease		Phase 4
NCT03384784	University of Pennsylvania\|National Institute on Drug Abuse (NIDA)	HIV Associated Cognitive Motor Complex	October 30, 2017	Phase 2
NCT00309725	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Alzheimer´s Disease		Phase 3
NCT00809835	Yale University\|National Institute on Drug Abuse (NIDA)	Cocaine Dependence	December 2007	Phase 2
NCT00000172	Janssen, LP\|National Institute on Aging (NIA)	Alzheimer Disease		Phase 3
NCT02872857	The University of Texas Health Science Center, Houston	Subarachnoid Hemorrhage	September 2016	Phase 1\|Phase 2
NCT01880099	Yale University\|National Institute on Drug Abuse (NIDA)	Nicotine Dependence	December 2013	Not Applicable
NCT01029132	Samsung Medical Center\|Janssen Korea, Ltd., Korea	Dementia	April 2007	Not Applicable
NCT00077727	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Schizophrenia	March 2003	Phase 3
NCT00645190	Xian-Janssen Pharmaceutical Ltd.	Alzheimer Disease	March 2004	Phase 3
NCT02420327	University of Maryland, Baltimore	Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor	September 2014	Not Applicable
NCT01416948	INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium\|U.S. Army Medical Research and Development Command	Posttraumatic Stress Disorder\|Traumatic Brain Injury	August 2011	Phase 2
NCT01129479	University of North Carolina, Chapel Hill\|Ortho-McNeil Neurologics, Inc.	Aphasia\|Stroke	October 2004	Not Applicable
NCT00416169	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Frontotemporal Dementia\|Pick Complex	May 2003	Phase 2
NCT02234752	Sheppard Pratt Health System	Schizophrenia\|Schizoaffective Disorder	September 2014	Phase 2
NCT01100775	University of Maryland, Baltimore\|National Institute of Mental Health (NIMH)	Schizophrenia	May 2010	Phase 2
NCT00226824	Parkinson´s Disease and Movement Disorders Center\|Ortho-McNeil Neurologics, Inc.	Tourette´s Syndrome\|Motor Tic Disorder\|Vocal Tic Disorder	September 2005	Phase 4
NCT01012167	University of Maryland, Baltimore\|National Institute of Mental Health (NIMH)	Schizophrenia	February 2010	Phase 2
NCT00230997	Neurological Research Center\|Ortho-McNeil Neurologics, Inc.	Lewy Body Disease	December 2002	Phase 3
NCT00969696	Yale University\|National Institute on Drug Abuse (NIDA)\|US Department of Veterans Affairs	Memory	August 2009	Phase 1
NCT00236431	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Dementia\|Alzheimer Disease	May 2001	Phase 3
NCT01734395	Janssen Korea, Ltd., Korea	Alzheimer´s Disease	March 2007
NCT03014323	Vanderbilt University Medical Center	Insulin Sensitivity\|Oxidative Stress	January 2017	Phase 1
NCT00216593	Janssen Pharmaceutica N.V., Belgium	Dementia\|Alzheimer Disease	December 2003	Phase 3
NCT00509067	Georgetown University\|National Institute of Mental Health (NIMH)\|Washington D.C. Veterans Affairs Medical Center	Schizophrenia	November 2007	Phase 2
NCT00195845	Cambridge Health Alliance\|Northwestern University	Bipolar Disorder	April 2003	Phase 4
NCT01548638	University of Pennsylvania	Nicotine Addiction	February 2012	Phase 2
NCT00814658	Janssen-Cilag Farmaceutica Ltda.	Dementia	June 2008	Phase 4
NCT01417429	Yale University\|National Institute on Drug Abuse (NIDA)	Smoking\|Tobacco Withdrawal	March 2010	Phase 1
NCT00161044	University of Maryland, Baltimore	Chronic Schizophrenia	September 2004	Not Applicable
NCT01054976	Janssen Korea, Ltd., Korea	Alzheimer´s Disease	October 2006	Phase 4
NCT03124355	Vanderbilt University Medical Center	Postural Tachycardia Syndrome	September 30, 2017	Phase 1
NCT00320736	North Suffolk Mental Health Association\|Janssen Medical Affairs	Schizophrenia\|Schizoaffective Disorder	January 2004	Phase 4
NCT00463879	Yale University\|National Alliance for Research on Schizophrenia and Depression	Schizophrenia	September 2005	Phase 2\|Phase 3
NCT00338117	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.\|Shire	Alzheimer´s Disease\|Dementia	August 1995	Phase 3
NCT01531153	Yale University\|National Institute on Drug Abuse (NIDA)	Addiction	September 2011	Not Applicable
NCT00750529	University Hospital, Clermont-Ferrand\|Janssen-Cilag Farmaceutica Ltda.	Alzheimer´s Disease	November 2008	Phase 1

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 59 mg/mL ( 205.32 mM )

1M HCl : 50 mg/mL ( 174.00 mM ; ultrasonic and adjust pH to 1 with HCl)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4801 mL	17.4004 mL	34.8008 mL
5 mM	0.6960 mL	3.4801 mL	6.9602 mL
10 mM	0.3480 mL	1.7400 mL	3.4801 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (8.70 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.70 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (8.70 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-

Galanthamine

6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-

(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol

Galantamine

Lycoremine

Jilkon

Galantamin

Lycoremin

6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, [4aS-(4aα,6β,8aR*)]-

(-)-Galanthamine

NSC 100058

Galantamina

BRN 0093736

(-)-Galantamine